Genetic Testing in South Africa

By Crystal Lubbe

February 13, 2025

Could genetic testing be the key to preventing sudden cardiac deaths in South Africa? The recent study investigated the use of genetic testing in South Africa, specifically through next-generation sequencing (NGS), to identify genetic causes of sudden unexpected deaths (SUD) in a young South African cohort. It analysed DNA from 51 SUD cases, focusing on 49 genes linked to inherited cardiac arrhythmogenic disorders. The findings revealed that approximately 4% of the deaths were likely due to genetic arrhythmic or cardiac conduction disorders. This study highlights the importance of genetic testing in understanding and preventing sudden cardiac deaths in South Africa.

Key Insights into Genetic Testing

The study identified 175 different missense variants, with 92.5% being known and documented, and 7.4% being novel. Most variants were of benign or likely benign significance, while a small percentage were pathogenic or of unknown significance. Post-mortem genetic testing revealed that about 4% (2/51) of the SUD cases had a genetic arrhythmic or cardiac conduction disorder as the probable cause of death. The study emphasises the need for better detection, treatment, and prevention of sudden cardiac deaths in South Africa, especially in light of the significant increase in noncommunicable diseases, particularly cardiovascular diseases. Utilising NGS and the Galaxy bioinformatic platform for variant annotation and interpretation demonstrates the potential of advanced genetic testing to elucidate the causes of sudden unexpected deaths.

Public Health Concerns Globally

Sudden cardiac death is a major public health concern globally. In sub-Saharan Africa, including South Africa, it accounts for an estimated 50% of all cardiovascular deaths. Unfortunately, there is a lack of reliable statistics on its incidence in these regions.
Previous studies have shown the value of genetic testing in determining the underlying causes of sudden unexpected deaths, especially in cases where traditional post-mortem investigations are inconclusive. Research indicates that sudden deaths are more common among males, particularly in the 40-49 age group, and often result from cardiovascular and respiratory incidents. Genetic factors are identified in a small percentage of these cases.

The Transformative Role of Genetic Testing in South Africa: Implications for Health and Society

The integration of next-generation sequencing (NGS) into the investigation of sudden unexpected deaths in South Africa could have profound economic implications. By reducing the need for repeated and costly diagnostic procedures, early identification of genetic causes can lead to targeted preventive measures and treatment strategies, potentially lowering healthcare costs over time. From a public health perspective, the insights gained from genetic testing can significantly inform strategies aimed at preventing sudden cardiac deaths. By identifying genetic predispositions, public health programs can focus on genetic screening and counseling, ultimately leading to improved health outcomes and reduced mortality rates.

For families affected by sudden unexpected deaths, genetic testing offers the possibility of closure by providing a clearer understanding of the cause of death. It also has important genetic implications for family members, enabling early intervention and preventive measures that can safeguard their health. Moreover, the study emphasises the necessity for more comprehensive epidemiological data on sudden cardiac deaths in South Africa. Such data is crucial for policymakers to develop and implement effective health strategies and interventions, addressing the growing burden of cardiovascular diseases.

In conclusion, genetic testing in South Africa is an essential tool for uncovering the underlying genetic causes of sudden unexpected deaths. It not only enhances healthcare outcomes but also helps in devising strategies to mitigate associated risks, thereby playing a transformative role in the health and well-being of individuals and communities.

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.